Providing Tools for Effective Care and Treatment of Anxiety Disorders (AD): Outcomes, Mediators and Moderators of Enhanced Extinction Learning

Providing Tools for Effective Care and Treatment of Anxiety Disorders (AD): Outcomes, Mediators and Moderators of Enhanced Extinction Learning - PROTECT-AD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00008743

Enrollment

620

Registered

2015-06-18

Start date

2015-12-03

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F40.1 F40.2 F40.00 F40.01 F41.0

Interventions

Group 1: Intensified psychological intervention, based on optimized extinction learning (IPI) 12 sessions a 100 minutes, over the course of 6 weeks (2 sessions per week/week 1 and 2, 3 sessions per we

Eligibility

Sex/Gender

All

Age

15 Years to 70 Years

Inclusion criteria

Inclusion criteria: • age 15 – 70 years • on or more of the following DSM-V Anxiety Disorders: Panic disorder, Agoraphobia, Social Anxiety Disorder, Specific Phobia • HAMA – Score = 18 • CGI – Score = 3 • Can attend Therapie regularly (with or without suppot) • Informed Consent

Exclusion criteria

Exclusion criteria: • Every reason the protocol may not be upheld (e.g. planned hospitalization within study time frame, planning to move away, etc.) • Current Suicidal tendency • DSM-V Bipolar Disorder • DSM-V Psychotic Disorder • DSM-V Borderline PD • Current treatment of other Mental Disorder (Drugs, Psychotherapy) • Current Alcohol, Benzodiazepine or other Substance Use Disorders • Severe medical illness/condition (every serious physical illness, including cardiovascular, kidney, endocrinological and neurological conditions, Hepatitis or other clinical findings that suggest a severe illness and may affect participation in the study)

Design outcomes

Primary

Measure	Time frame
Stronger reduction of anxiety symptoms in the IPI group than in the TAU group, Anxiety symptoms are assessed using the HAM-A at Baseline, Post/after session twelve and Follow up/after six months	—

Secondary

Measure	Time frame
CGI (symptom severity), CIDI (DIA-X) (categorical diagnosis), DSM-5 Cross-D (anxiety), BSI (SCL-90) (psychopathol. symptoms), BDI-II (depressive symptoms), ASI (anxiety sensitivity), PAS (panic/agoraphobia), ACQ (cognition in agoraphobia) BSQ (bodily anxiety/cognition/avoidance) MI (agoraphobic avoidance), GAD-7 (worrying), LSAS (social anxiety), DSM-5 Specific Phobia Scale WHODAS 2.0 (disability), EQ5D (quality of life), All measurements are taken three times (Baseline, Post/after session twelve, Follow up/after six months), the BSI additionally during course of treatment	—

Measure

Time frame

CGI (symptom severity), CIDI (DIA-X) (categorical diagnosis), DSM-5 Cross-D (anxiety), BSI (SCL-90) (psychopathol. symptoms), BDI-II (depressive symptoms), ASI (anxiety sensitivity), PAS (panic/agoraphobia), ACQ (cognition in agoraphobia) BSQ (bodily anxiety/cognition/avoidance) MI (agoraphobic avoidance), GAD-7 (worrying), LSAS (social anxiety), DSM-5 Specific Phobia Scale WHODAS 2.0 (disability), EQ5D (quality of life), All measurements are taken three times (Baseline, Post/after session twelve, Follow up/after six months), the BSI additionally during course of treatment

—

Countries

Germany

Contacts

Public ContactIngmar Heinig

Technische Universität Dresden, Institut für Klinische Psychologie und Psychotherapie

ingmar.heinig@tu-dresden.de+49-(0)351-463-36889

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 3, 2026